1. Home
  2. SOAR vs JAGX Comparison

SOAR vs JAGX Comparison

Compare SOAR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.56

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.70

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOAR
JAGX
Founded
2021
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOAR
JAGX
Price
$0.56
$0.70
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
3.1M
10.5M
Earning Date
11-13-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.32
N/A
Revenue
$58,312,000.00
$11,785,000.00
Revenue This Year
N/A
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
$0.35
N/A
Revenue Growth
N/A
12.45
52 Week Low
$0.41
$0.64
52 Week High
$6.48
$25.75

Technical Indicators

Market Signals
Indicator
SOAR
JAGX
Relative Strength Index (RSI) 36.59 41.37
Support Level $0.41 $0.68
Resistance Level $0.73 $0.80
Average True Range (ATR) 0.08 0.18
MACD 0.01 -0.01
Stochastic Oscillator 39.57 5.12

Price Performance

Historical Comparison
SOAR
JAGX

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: